Discovering new compounds to treat global infectious disease

发现治疗全球传染病的新化合物

• 批准号: 9100871
• 负责人: Emily R Derbyshire
• 金额: $ 24.9万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9100871
• 关键词: Address; Africa; Antimalarials; Antiparasitic Agents; Area; Asia; Award; Biological Assay; Biological Process; Biology; Blood; Cessation of life; Chemicals; Communicable Diseases; Complement; Country; Culicidae; Development; Disease; Drug Targeting; Drug resistance; Enzymatic Biochemistry; Enzymes; Focus Groups; Genes; Genetic; Goals; Health; Hepatocyte; Human; Image; In Vitro; Infection; Infectious Diseases Research; Integration Host Factors; Knock-out; Learning; Libraries; Life; Liver; Malaria; Methodology; Molecular; Parasites; Phase; Plasmodium; Positioning Attribute; Process; Proteins; Public Health; Reporting; Research; Research Personnel; South America; Staging; Testing; Therapeutic; Time; Training; Transgenic Organisms; Work; World Health Organization; abstracting; base; drug discovery; drug mechanism; global health; high throughput screening; in vivo; inhibitor/antagonist; insight; interest; medical schools; neglected tropical diseases; novel; novel therapeutics; parasite invasion; programs; research study; screening; skills; small molecule; small molecule inhibitor; small molecule libraries; tenure track; tool

Abstract Current estimates from the World Health Organization suggest that global cases of infectious disease are rising. Malaria remains a devastating disease in poor and undeveloped countries in Africa, South America and Asia, where nearly one million deaths were reported in 2009. In these areas, parasites can rapidly develop drug resistance, which erodes the efficacy of antimalarials. Thus new drugs and the identification of novel targets are desperately needed to treat malaria. My graduate studies with Prof. Michael Marletta (UC Berkeley) involved detailed mechanistic studies on enzymes that are important to human health. To learn more about infectious disease and chemical biology I joined Prof. Jon Clardy's lab at Harvard Medical School (HMS). At HMS I received training to work with both the blood and liver stages of the malaria parasite. This training allowed me to develop a high-throughout screen to identify inhibitors of liver stage malaria. In the next two years I plan to screen several small molecule libraries for potential therapeutics to treat malaria (Specific Aim 1). During my time at HMS I will also train with several experts to learn how to generate genetic knockouts in malaria, raise drug resistant parasite strains, and maintain transgenic mosquito lines. I can then use this training to evaluate the biological processes of the parasite that my identified liver stage malaria inhibitors target (Specific Aim 2) and to biochemically characterize the protein targets (Specific Aim 3). The training needed to address Specific Aims 2 and 3 will be completed at HMS during the K99 phase of the award, but most of the experiments will be completed during the independent phase of the award. I plan to apply for a tenure-track academic position with the goal of leading a research group focused on characterizing essential processes and proteins of the malaria parasite that facilitate the disease process. HMS is ideally suited for the proposed K99 training period as it has a state-of-the-art high- throughput screening facility and is a leader in infectious disease research with programs like the Harvard Malaria Initiative. I believe the courses and training I receive in the next two years will broaden my understanding of parasite biology and nicely complement my previous skills in enzymology to make me uniquely suited to work on global infectious disease as an independent researcher.

摘要